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604 The Journal of Thoracic and Cardbjective: Coronary artery bypass graft surgery remains associated with significant
ostoperative cardiovascular morbidity and mortality in high-risk patients. MC-1
pyridoxal-5=-phosphate monohydrate) inhibits purinergic receptors and intracellu-
ar influx of Ca2, thereby reducing cellular injury during experimental ischemia
nd reperfusion. The MEND-CABG trial tested the hypothesis that MC-1 reduces
ardiovascular morbidity and mortality after coronary artery bypass graft.
ethods: In a phase 2, double-blinded, placebo-controlled study, 901 patients
cheduled for coronary artery bypass graft surgery with cardiopulmonary bypass
nd at high risk for subsequent cardiac or neurologic complications were randomly
ssigned to receive oral MC-1 (250 mg or 750 mg/d once daily) or placebo
eginning 3 to 10 hours prior to surgery and continued to postoperative day 30.
esults: At 30 days, MC-1 250 mg (compared with placebo) reduced the
omposite of death, nonfatal cerebral infarction, and nonfatal myocardial in-
arction by 14.0% (P  .3124) with peak creatinine kinase–myocardial band
50 ng/mL (prespecified primary end point); 32.3% (P  .0349) with peak
reatinine kinase–myocardial band 70 ng/mL; and 37.2% (P  .0283) with
eak creatinine kinase–myocardial band 100 ng/mL. Myocardial infarctions
ith peak creatinine kinase–myocardial band100 ng/mL were reduced by
7.2% in the MC-1 250-mg group versus placebo (P  .0083). Greater efficacy
as demonstrated with 250 mg than with the 750-mg dose of MC-1.
onclusions: In high-risk patients undergoing coronary artery bypass graft, treat-
ent with MC-1 did not significantly affect the prespecified primary end point but
as associated with a significant reduction in perioperative myocardial infarction
ith creatinine kinase–myocardial band 100 ng/mL. A larger, well-powered trial
s needed to evaluate the cardioprotective effects of MC-1.
oronary artery bypass graft (CABG) surgery effectively relieves angina and
results in longer survival in specific subgroups of patients with complex
coronary disease and left ventricular dysfunction.1-3 Due to the high inc
ence of coronary artery disease worldwide, as well as the effectiveness of this
urgical procedure, CABG surgery makes up 1 of the top 10 most frequently
erformed procedures in North America and Europe.4,5 Despite the benefits o
ABG surgery, the procedure is associated with a risk of perioperative mortality,
yocardial infarction, unstable angina, heart failure, life-threatening arrhythmia,
enal insufficiency, and stroke, often due to episodes of ischemia and reperfu-
ion.6-10 The impact of these complications is significant with incidence rat
eath and major cardiovascular and cerebrovascular events following CABG sur-
ery of up to 20% depending on the patient’s risk profile and diagnostic criteria.11-16
iovascular Surgery ● June 2007
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Plthough advances in surgical techniques, anesthetic m
gement, and postoperative care have resulted in a st
ecline in post-CABG morbidity and mortality during 
ast 2 decades,17,18 there clearly remains a need to red
he number of complications associated with cardiac 
ery. Considering the substantial number of patients w
ndergo CABG every year along with the incidence
equelae, cardioprotection and neuroprotection represe
ignificant unmet medical needs.
MC-1 is an investigational drug that contains pyrido
=-phosphate monohydrate (P-5=-P). P-5=-P is a naturall
ccurring metabolite of pyridoxine and is formed in m
alian cells by phosphorylation and oxidation reactio
C-1 is a purinergic (P2) receptor antagonist that bl
ntracellular influx of Ca2, thereby reducing cell dama
uring experimental episodes of ischemia and reperfusion19
 phase 2 dose-ranging, single-blinded study (MEND
valuated the effects of 10 mg/kg/d MC-1 given for up 
ays in patients at high risk for ischemic complica
uring percutaneous coronary intervention (PCI).20 Results
emonstrated a decrease in infarct size over the firs
ours following PCI, suggesting the cardioprotective pr
rties of MC-1 in the setting of ischemia and reperfu
he MC-1 to Eliminate Necrosis and Damage in CA
MEND-CABG) trial was a phase 2 study that intende
valuate the potential cardio- and neuroprotective effects
C-1 in patients undergoing CABG with cardiopulmon
ypass and considered at high risk for perioperative va
ar events.
aterials and Methods
tudy Design and Patient Selection
ollowing approval by individual Ethics Committees and Ins
ional Review Boards, enrollment for the double-blinded, place
ontrolled MEND-CABG trial was conducted at 40 center
anada and the United States (Appendix E1) between April 
nd July 2005. Patients eligible for the study were those sche
or CABG surgery with cardiopulmonary bypass but without
ociated valve surgery who were considered at high risk
erioperative cardio- and/or cerebrovascular complications 
Abbreviations and Acronyms
ATP  adenosine triphosphate
CABG  coronary artery bypass graft
CEC  Clinical Endpoint Committee
CK-MB creatinine kinase–myocardial band
ECG  electrocardiogram
MI myocardial infarction
P-5=-P  pyridoxal-5=-phosphate monohydrate
PCI  percutaneous coronary intervention
POD  postoperative dayording to 2 or more of the following criteria: age 65 years; M
The Journal of Thoracic4
.
urrent smoker; history of diabetes mellitus requiring treatm
ther than diet; history of nondisabling stroke, transient isch
ttack, or carotid endarterectomy; prior peripheral artery surger
ngioplasty; recent myocardial infarction (MI) (48 hours and 6
eeks before surgery); evidence of left ventricular dysfunctio
ongestive heart failure; need for urgent CABG; renal dysfunc
ith serum creatinine between 133 and 250 mol/L (1.5–2.8
g/dL); or presence of stenosis (50%) in 1 carotid artery
atients with planned associated valve surgery, concurrent car
ndarterectomy, aortic dissection repair, aortic root reconstructi
r surgery for atrial fibrillation were excluded, as were pa
ith current cardiogenic shock, left ventricular rupture, ventric
eptal rupture, papillary muscle rupture, uncontrolled diabe
fasting plasma glucose 24 mmol/L (432 mg/dL)], creatini
250 mol/L (2.8 mg/dL), liver cirrhosis, chronic active hepat
evere liver dysfunction, MI occurring 48 hours prior to plann
ABG surgery, history of malignancy during the last 5 y
otential for pregnancy, or history of alcohol or drug abuse w
he past year. Finally, patients who could not be screened a
 hours before the scheduled CABG were excluded.
After written informed consent was obtained, patients w
andomly assigned in a 1:1:1 ratio (using an interactive 
esponse system) to receive MC-1 250 mg, MC-1 750 m
atching placebo tablets administered orally once daily. The 
ose of study medication was administered 3 to 10 hours pr
ABG surgery and treatment continued for 30 days after surgery.
uring CABG surgery, the use of cardiopulmonary bypass, mod-
rate systemic hypothermia (34°C), and routine anticoagulation
ere required per protocol. Patients unable to swallow pills post-
peratively were allowed to receive study medication through a
asogastric tube. During the 90-day postoperative period, patient
bservations were carried out through 72 hours, at postoperative
ay (POD) 4, at discharge, at POD 30, and at POD 90.
tudy End Points and Definitions
he primary efficacy end point was the difference between treat-
ent groups in the combined incidence of cardiovascular death,
onfatal MI, and nonfatal cerebral infarction up to and including
OD 30. Secondary efficacy end points included individual com-
onents of the combined end point, area under the curve of
reatinine kinase–myocardial band (CK-MB) within the first 24
ours post-CABG, all-cause mortality, and composite and compo-
ent end points up to POD 90. An independent Clinical Endpoint
ommittee (CEC) composed of cardiologists and neurologists
xperienced in patient care reviewed all potential episodes of the
rimary end point components, and their determination was used
n the final analysis. Each reported death, stroke, and MI was
lassified according to predetermined guidelines. All deaths with-
ut an identifiable noncardiovascular cause were attributed to a
ardiovascular cause. Myocardial infarction was defined based on
entral laboratory or core electrocardiogram (ECG) laboratory data
s follows: (1) a peak CK-MB value 50 ng/mL, or 35 ng/mL
ith ECG evidence of Q-wave, on days up to and including POD
; 2) a peak CK-MB 25 ng/mL or new Q-wave occurring after
OD 4; or (3) a Q-wave or non-Q-wave MI identified by the
nvestigator and confirmed by the CEC. In addition, other previ-
usly used criteria13 were also applied to the definition of nonf
I (and composite end point) as a post hoc analysis. For patients
and Cardiovascular Surgery ● Volume 133, Number 6 1605
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1
CSPith CK-MB contributing as at least 1 source of the susp
vent, the additional definitions of CK-MB 70 ng/dL and
K-MB 100 ng/dL were applied to the adjudicated populatio
dentify patients with more significant myocardial damage.
Patient blood samples were collected before CABG surg
baseline) and 4, 8, 12, 16, 24, 36, 48, 72, and 96 hours and
0 days after CABG surgery. All samples were submitted 
entral laboratory (Cirion BioPharm Research, Inc, Laval, Que
anada) for CK-MB measurements. Electrocardiograms were p
ormed at baseline, on POD 2, 4, 30, and 90 and analyzed a
ng to the Minnesota Code21 by an independent core laborato
Dynacare Laboratories, Edmonton, Alberta, Canada). All 
cheduled CK-MB determinations and ECGs were also recor
nd adjudicated by the CEC.
Cerebral infarction was defined as any new sudden onset 
eurologic deficit lasting 24 hours following exclusion of int
ranial hemorrhage by imaging (computed tomography scan
agnetic resonance imaging). All patients suspected clinically
aving a stroke or transient ischemic attack were require
ndergo a neurologic examination (conducted by a neurologis
nternist with expertise in cerebral vascular disease) within
ours of onset of symptoms, in addition to cerebral imaging
tatistical Methods
he sample size estimate assumed a primary event rate of 
ith placebo. In this phase 2 study, a sample size of 300 p
er treatment group had 78% power to detect a relative redu
f 37% in any of the 2 active groups with a 2-sided signi
evel of .20 for both comparisons with placebo. The pri
nalysis compared the incidence in each active treatment g
ith that in the placebo group using 2 2 tests: 1 for the compa-
son of MC-1 250 mg/d versus placebo and 1 for the comp
f MC-1 750 mg/d versus placebo with no adjustments for 
le comparisons. End points were computed on a per-patient b
or the components of the primary efficacy end point at PO
nd for the composite end point at POD 90, 2 tests comparing th
 groups were used. If significant, 2 tests with 1 degree 
reedom were performed for comparisons against placebo. For
omponents of the primary efficacy end point at POD 90, an
ere based on time to event and groups were compared 
og–rank tests. Again, pairwise comparisons were undertaken o
hen the overall comparison was significant. Areas under 
urve of CK-MB were compared across groups using an ana
f variance. Aside from the primary analysis, all other stati
ests were performed at a significance level of .10.
rial Organization
 Steering Committee supervised the scientific conduct of
tudy, and an independent Data and Safety Monitoring B
versaw safety and ethical issues. The clinical sites, CEC, 
ore Laboratory, and Central Laboratory shared the responsib
f identifying potential end point events, and the CEC was re
ible for adjudicating all of them. Project management, data 
gement, and Canadian site management were conducted by
ontreal Heart Institute Coordinating Center (Montreal, Canad
hich also prepared the randomization codes. Site managemen
he United States was conducted by Duke Clinical Research 
ute (Raleigh, NC). Statistical analyses were performed by thefi
606 The Journal of Thoracic and Cardiovascular Surgery ● Junand
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ontreal Heart Institute Coordinating Center independently of 
ponsor. Medicure Inc (Winnipeg, Canada) sponsored the stu
esults
atient Characteristics
he demographics and clinical characteristics of the 
andomized patients were relatively well balanced betw
he 3 treatment groups (Table 1). There were slightly f
atients with prior MIs, hypertension, heart failure, re
I, and need for urgent CABG in the placebo group
lightly more patients with prior PCIs, diabetes, and pe
ral vascular disease. Overall, the mean patient age wa
ears (range, 34 –95 years), and 79% of patients were 
he patients’ flow in the study is shown in Figure 1.
fficacy Analyses
f the 901 patients, 217 (24.1%) reached the prespec
rimary end point at POD 30 defined as cardiovasc
eath, nonfatal cerebral infarction, and nonfatal MI (p
K-MB 50 mg/mL) distributed as follows: 25.1% (
99) placebo, 21.6% (65/301) 250 mg/d MC-1, and 25
77/301) 750 mg/d MC-1 (Table 2). At 30 days, the 25
ose of MC-1 reduced the combined end point of ca
ascular death, nonfatal cerebral infarction, and nonfatal
y 14.0% (P  .3124) with peak CK-MB 50 ng/mL;
2.3% (P  .0349) with peak CK-MB 70 ng/mL; and
7.2% (P  .0283) with peak CK-MB 100 ng/mL. Com
ared with placebo, MC-1 250 mg reduced MIs with peak
K-MB 50 ng/mL by 15.2% (P  .2988), MIs with peak
K-MB 70 ng/mL by 37.6% (P  .0192), and MIs with
eak CK-MB 100 ng/mL by 47.2% (P  .0083).
MC-1 750 mg did not significantly affect the composite
rimary end point when more restrictive CK-MB criteria
ere employed. However, MC-1 750 mg reduced MIs with
eak CK-MB 100 ng/mL by 47.2% (P  .0083) com-
ared with placebo at POD 30. Among patients with adju-
icated MIs, the area under the curve of CK-MB (0–24
ours) was 1765.5 1148.7 in the placebo group, 1581.5
071.9 in the MC-1 250-mg group, and 1397.9  962.7 in
he MC-1 750-mg arm (P  .1737). Finally, similar trends
s those described at POD 30 were observed at POD 90
Table 3).
afety Analyses
C-1 administered for 30 days was generally well toler-
ted. Both in the MC-1 and placebo groups, 69% to 73% of
he patients experienced 1 adverse event from randomiza-
ion to POD 4 or from POD 4 to end of trial (Table 4
vents were considered to be mild to moderate in intensity.
otably, the incidence of hypotension up to POD 4 was
lightly higher with MC-1 750 mg, as was vomiting from
OD 4 to the end of the trial. Finally, the incidence of atrial
brillation from POD 4 to end of trial was 11.9% with
e 2007
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Placebo, 5.7% with MC-1 250 mg, and 6.0% with M
50 mg.
iscussion
he primary result of this study is that MC-1 did not
ignificantly affect the prespecified composite end point of
ardiovascular death, nonfatal MI (peak CK-MB level 50
g/mL), and nonfatal cerebral infarction in this phase 2
tudy of high-risk CABG patients. However, MC-1 admin-
stered at a dose of 250 mg daily in the MEND-CABG trial
as associated with a decreased risk for major cardiovas-
ular events with the application of higher thresholds of
K-MB applied to the criteria for MI detection in a post hoc
nalysis. Reductions of 32.3% and 37.2% of the combined
nd point of cardiovascular death, nonfatal stroke, and non-
atal MI were obtained with MC-1 when CK-MB cutoff
alues of 70 and 100 ng/mL were used, respectively, in
hese exploratory analyses. Furthermore, 250 mg of MC-1
educed MIs with peak CK-MB 100 ng/mL by 47.2%.
onsidering that levels of elevated CK-MB in the post-
ABG setting correlate with the extent of myocardial in-
arction as assessed with magnetic resonance imaging22
ABLE 1. Characteristics of the study population
ex (% male)
ge (mean y  SD)
ace (% Caucasian)
revious MI (%)
revious PCI (%)
revious CABG (%)
ngina (%)
trial fibrillation (%)
ilent ischemia (%)
ypertension (%)
iabetes (%)
ypercholesterolemia (%)
eripheral vascular disease (%)
ongestive heart failure (%)
urrent smoker (%)
istory of diabetes mellitus requiring treatment other than diet (%
vidence of LVD or CHF (%)
istory of nondisabling stroke, TIA, or endarterectomy (%)
rgent CABG intervention required (%)
istory of MI 48 hours to 6 weeks prior to study entry (%)
rior peripheral artery surgery or angioplasty (%)
reatinine 133–250 mol/L (%)
resence of at least 1 carotid artery stenosis 50% (%)
ge 65 years (% patients)
I, Myocardial infarction; PCI, percutaneous coronary intervention; CA
entricular dysfunction; CHF, congestive heart failure.ost hoc results of the MEND-CABG trial suggest that b
The Journal of ThoracicC-1 may be particularly effective in preventing larger,
ore significant perioperative infarcts.
There is a linear relationship between postoperative
K-MB elevations and 1-year mortality after CABG.23,24 In
he GUARDIAN trial, peak CK-MB values after CABG of
25, 25 to 49, 50 to 99, and 100 ng/mL were associated
ith 6-month mortality risks of 3.4%, 5.8%, 7.8%, and
0.2%, respectively.25 In another study of 3812 patie
ndergoing CABG, the link between peak CK-MB and
-year mortality was shown only in patients with values
bove 88 ng/mL.26 Because of this relationship betwe
K-MB and mortality, several large clinical trials such as
RIMO–CABG have used a cutoff CK-MB value of 100
g/mL to diagnose perioperative MIs.12,13 In the presen
tudy, the observed incidence of nonfatal MIs in the placebo
roup of 23.1% based on criteria utilized for event adjudi-
ation (peak CK-MB 50 ng/mL) was much higher than
he reported 11% to 14% incidence in similar popula-
ions.11,13,23 This higher than expected rate of MIs, in -
rast with rates of cardiovascular deaths and nonfatal cere-
ral infarctions that were those we had predicted, suggest
hat our cutoff CK-MB value used to diagnose MI may have
Placebo
(n  299)
MC-1 250 mg
(n  301)
MC-1 750 mg
(n  301)
All
(n  901)
80.3 76.7 79.1 78.7
66 10 65 11 65 10 66 10
93.3 92.0 93.4 92.9
51.4 58.8 56.3 55.5
25.8 20.7 20.6 22.4
3.7 2.7 3.7 3.3
82.1 79.7 78.1 80.0
5.1 6.0 4.7 5.2
6.8 5.2 8.4 6.8
72.5 77.0 74.4 74.6
46.2 39.6 43.8 43.1
82.8 79.7 80.1 80.9
17.6 14.4 17.6 16.5
13.5 19.8 15.1 16.1
29.8 27.6 26.8 28.0
43.8 36.5 41.1 40.5
21.1 30.2 27.8 26.4
12.0 12.0 12.9 12.3
71.9 76.4 77.8 75.4
24.1 28.6 27.5 26.7
17.4 12.0 11.3 13.5
8.0 8.3 7.9 8.1
7.7 5.6 5.0 6.1
58.5 54.2 54.6 55.8
oronary artery bypass grafts; TIA, transient ischemic attack; LVD, left)
BG, ceen too low in the peri-CABG setting. When using the
and Cardiovascular Surgery ● Volume 133, Number 6 1607
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1
CSPutoff CK-MB value of 100 ng/mL, the incidence of the
omposite end point of cardiovascular death, nonfatal cere-
ral infarction, and nonfatal MI was 16.4% in the placebo
roup, in line with the rate (15%) we used in our power
alculation for this high-risk population.
The reduction in postoperative MIs with 750 mg of
C-1 versus placebo was not larger than that obtained with
50 mg per day. The rate of nonfatal cerebral infarctions
Placebo
n = 299 n = 301 
Randomized
n = 9
Completed study 
n = 263 
Withdrawn 
n = 36 
Completed study 
n = 266 
Withdrew consent (12) 
Investigator's decision (2) 
Lost to follow-up (3) 
Death (5) 
Refused study procedures (4) 
Other (10)
Withdrew consent (13)
Investigator's decision
Lost to follow-up (2) 
Death (8) 
Refused study procedu
Other (7)
MC-1 250 
Figure 1. Patient flow in the MEND-CABG study. The
analysis using the intent-to-treat approach.
ABLE 2. POD 30 efficacy results—composite and compo
nd point
Placebo
(n  299)
ardiovascular death, nonfatal MI (peak CK-MB
50 ng/mL), and nonfatal cerebral infarction
75 (25.1%)
ardiovascular death 4 (1.3%)
onfatal MI (peak CK-MB 50 ng/mL) 69 (23.1%)
onfatal cerebral infarction 5 (1.7%)
ardiovascular death, nonfatal MI (peak CK-MB
70 ng/mL), and nonfatal cerebral infarction
60 (20.1%)
ardiovascular death, nonfatal MI (peak CK-MB
100 ng/mL), and nonfatal cerebral infarction
49 (16.4%)
onfatal MI (peak CK-MB 70 ng/mL) 54 (18.1%)
onfatal MI (peak CK-MB 100 ng/mL) 43 (14.4%)I, Myocardial infarction; CK-MB, creatinine kinase–myocardial band.
608 The Journal of Thoracic and Cardiovascular Surgery ● Junlso tended to be higher in the 750-mg arm, an observation
hat was unexpected and perhaps may have been due to the
lay of chance. However, it is not clear whether the slightly
igher incidence of hypotension associated with 750 mg of
C-1 in the first 4 postoperative days could in part be
esponsible for this finding. In light of these results, the
eneficial effects observed with 250 mg of MC-1 suggest
hat this dosage may be the preferred one in future trials.
MC-1 750 mg 
n = 301 
ents 
thdrawn 
 = 35 
Completed study 
n = 260 
) 
Withdrew consent (12) 
Investigator's decision (0) 
Lost to follow-up (2) 
Death (7) 
Refused study procedures (12) 
Other (8)
Withdrawn 
n = 41 
andomized patients were all involved in the efficacy
end points
MC-1 250 mg
(n  301)
MC-1 750 mg
(n  301) P value
65 (21.6%) 77 (25.6%) .3124 placebo vs 250 mg
.8885 placebo vs 750 mg
4 (1.3%) 4 (1.3%) .9999 (overall)
59 (19.6%) 71 (23.6%) .4393 (overall)
6 (2.0%) 10 (3.3%) .3642 (overall)
41 (13.6%) 47 (15.6%) .0349 placebo vs 250 mg
.1543 placebo vs 750 mg
31 (10.3%) 34 (11.3%) .0283 placebo vs 250 mg
.0709 placebo vs 750 mg
34 (11.3%) 38 (12.6%) .0407 (overall)
.0192 placebo vs 250 mg
.0647 placebo vs 750 mg
23 (7.6%) 23 (7.6%) .0061 (overall)
.0083 placebo vs 250 mg
.0083 placebo vs 750 mg pati
01 
Wi
n
 
 (0) 
res (5
mg 
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PMC-1 was generally well tolerated in this study. The
ajority of adverse events during the trial were associated
ith the surgical procedure and not with the study drug. The
elatively high incidence of atrial fibrillation, anemia, and
leural effusions was expected in this perioperative setting.
he lower incidence of atrial fibrillation observed in the
C-1 groups (5.7% and 6.0%) compared with the placebo
roup (11.9%) between POD 4 and the end of the trial is
ABLE 3. POD 90 efficacy results—composite and compo
ndpoint
Placebo
(n  299)
ardiovascular death, nonfatal MI (peak CK-MB
 50 ng/mL), and nonfatal cerebral infarction
80 (26.8%)
ardiovascular death* 4 (1.3%)
onfatal MI (peak CK-MB  50 ng/mL)* 74 (24.7%)
onfatal cerebral infarction* 5 (1.7%)
ardiovascular death, nonfatal MI (peak CK-MB
 70 ng/mL), and nonfatal cerebral infarction
61 (20.4%)
ardiovascular death, nonfatal MI (peak CK-MB
 100 ng/mL), and nonfatal cerebral infarction
50 (16.7%)
onfatal MI (peak CK-MB  70 ng/mL) 55 (18.4%)
onfatal MI (peak CK-MB  100 ng/mL) 44 (14.7%)
Comparison of groups by log–rank test. MI, Myocardial infarction; CK-M
ABLE 4. Safety results*
ariable
rom randomization to POD 4
atients experiencing one or more SAEs
ercent of SAEs considered by the investigator unlikely or not re
atients experiencing one or more AEs
ercent of AEs considered by the investigator unlikely or not rela
trial fibrillation
nemia
ypotension
ausea
rom POD 4 to end of trial
atients experiencing one or more SAEs
ercent of SAEs considered by the investigator unlikely or not re
atients experiencing one or more AEs
ercent of AEs considered by the investigator unlikely or not rela
leural effusion
trial fibrillation
ausea
eripheral edema
omiting
The safety population was comprised of patients who took 1 dose
ostoperative day.
The Journal of Thoracicntriguing. Whether this result is due to a direct effect of
C-1 on the atria, reduced atrial stretch secondary to the
ower incidence of large myocardial infarcts, or represents
imply a chance finding cannot be determined in this trial.
onsidering the incidence and morbidity associated with
trial fibrillation in the postoperative setting, the effect of
C-1 on atrial fibrillation should be carefully evaluated in
uture studies.
end points
MC-1 250 mg
(n  301)
MC-1 750 mg
(n  301) P value
67 (22.3%) 78 (25.8%) .4047 (overall)
5 (1.7%) 4 (1.3%) .9272 (overall)
60 (19.9%) 72 (23.8%) .3327 (overall)
6 (2.0%) 11 (3.6%) .2362 (overall)
42 (14.0%) 48 (15.9%) .0362 placebo vs 250 mg
.1516 placebo vs 750 mg
32 (10.6%) 35 (11.6%) .0299 placebo vs 250 mg
.0710 placebo vs 750 mg
34 (11.3%) 38 (12.6%) .0289 (overall)
.0144 placebo vs 250 mg
.0489 placebo vs 750 mg
23 (7.6%) 23 (7.6%) .0037 (overall)
.0059 placebo vs 250 mg
.0057 placebo vs 750 mg
atinine kinase–myocardial band.
Placebo
(n  294)
MC-1 250 mg
(n  296)
MC-1 750 mg
(n  299)
37 (12.6%) 36 (12.2%) 42 (14.0%)
to MC-1 100% 93.9% 97.3%
205 (69.7%) 217 (73.3%) 216 (72.2%)
o MC-1 95.0% 94.9% 94.4%
54 (18.4%) 56 (18.9%) 63 (21.1%)
43 (14.6%) 52 (17.6%) 34 (11.4%)
32 (10.9%) 37 (12.5%) 39 (13.0%)
31 (10.5%) 23 (7.8%) 32 (10.7%)
76 (25.9%) 80 (27.0%) 76 (25.4%)
to MC-1 94.9% 94.8% 89.4%
213 (72.4%) 203 (68.6%) 213 (71.2%)
o MC-1 95.6% 94.0% 93.3%
22 (7.5%) 27 (9.1%) 31 (10.4%)
35 (11.9%) 17 (5.7%) 18 (6.0%)
18 (6.1%) 18 (6.1%) 29 (9.7%)
20 (6.8%) 23 (7.8%) 22 (7.4%)
10 (3.4%) 8 (2.7%) 20 (6.7%)
udy medication. AE, Adverse event; SAE, serious adverse event; POD,nentlated
ted t
lated
ted t
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CSPP-5=-P, the active ingredient of MC-1, is a metaboli
yridoxine (vitamin B6). Although anecdotal evidence su-
ests a role for vitamin B6 in cardiovascular health, recen
arge-scale clinical trials have failed to demonstrate 
enefit.27,28 In contrast, MC-1 has shown cardioprotecti
ffects in animal models, and data from phase 2 trial
ncouraging.20 This discrepancy may be explained by 
act that doses of pyridoxine above 25 mg produce 
hange in plasma levels of P-5= P.29 Thus, it is not possib
o achieve therapeutic plasma levels of P-5=-P (such as thos
btained with the doses of MC-1 used in this study) th
itamin B6 supplementation. MC-1 is a purinergic P2--
eptor antagonist that inhibits the binding of adeno
riphosphate (ATP) and thereby decreases calcium flux 
ardiomyocytes.30,31 Extracellular ATP is released fro
latelets and nerve endings during various stress conditi
uch as ischemia or reperfusion injury, and acts on pur
ic P2-receptors on cardiomyocytes to initiate an increas
ntracellular calcium. Because calcium overload leads 
ell damage and is responsible for cell death during 
mia followed or not by reperfusion, reduction in calc
nflux may explain the beneficial effects observed w
C-1 in animal19 and clinical20 studies. The majority o
yocardial infarctions occurred within the first few d
fter CABG surgery in this study, and the reduction 
C-1 therefore was already observed at POD 4. The p
, MEND-CABG trial extends previous results in a m
arger study conducted in a population of patients that
t high risk of cardiovascular events, in the settin
yocardial ischemia and reperfusion.
In conclusion, treatment with MC-1 in high-risk pati
ndergoing CABG with cardiopulmonary bypass did 
ignificantly affect the prespecified primary end point 
as associated with a significant reduction in periopera
yocardial infarctions in a post hoc analysis using CK
hresholds of 70 and 100 ng/mL. A larger, well-pow
rial is needed to further evaluate the cardioprotective
ects of MC-1.
Dr Tardif holds the Pfizer and Canadian Institutes of H
esearch chair in atherosclerosis. We thank the patients 
articipated, the site investigators and coordinators, the person
t the Montreal Heart Institute Coordinating Center and D
linical Research Institute, as well as the study committees. S
ng committee: J.–C. Tardif (chair), M. Carrier, R. Côté, G. Du-
uis, R. Emery, R. Harrington, T. Heinonen, and D. Kandzari.
linical Endpoint Committee: P. L’Allier (chair), I. Chayer, J.
régoire, R. Ibrahim, S. Lanthier. Data Safety Monitoring Board:
. Ferguson (chair), A. Allen, C.E. Buller, J.D. Easton, A.M.
incoff.
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anada—Dr Michel Carrier and Micheline Roy (Montreal Heart
nstitute, Montreal, Quebec); Dr Pierre Ghosn, Nicole Huart, and
uzanne Bisaillon (St-Luc Hospital, Montreal, Quebec); Dr Pierre
agé, Dr Robert Cossette, and Carole Fortier (Sacré-Coeur Hos-
ital, Montreal, Quebec); Dr Jean–François Morin and Maggie
recca (Jewish General Hospital, Montreal, Quebec); Dr François
agenais and Gladys Dussault (Laval Hospital, Quebec City,
uebec); Dr Terry Yau and Katherine Tsang (Toronto General
ospital, Toronto, Ontario); Dr André Lamy and Rosanne Kent
Hamilton Health Sciences Corp, Hamilton, Ontario); Dr Craig
rown, Karen Crane, and Anne Williston (St-John Regional Hos-
ital, St-John, New Brunswick); Dr Camille Hancock Friesen, Dr
ohn Sullivan, Helen Gravel, and Janice MacIsaac (Queen Eliza-
eth II, Halifax, Nova Scotia); Dr Eric Jamieson and Cindy Bryson
St-Paul’s Hospital, Vancouver, British Columbia); Dr Guy Fradet,
ebecca Fox, and Sandy Macleod (Vancouver Hospital, Vancou-
er, British Columbia); Dr Andrew Maitland and Marg Holland
Foothills Medical Centre, Calgary, Alberta); Dr Khaled Nour, Dr
olette Seifer, and Barbara McEwen (St-Boniface General Hos-
ital, Winnipeg, Manitoba); Dr Benoit de Varennes, Carole Albert,
nd Connie Vaccaro (Royal Victoria Hospital, Montreal, Quebec).
United States—Dr John Harlan and Juli Burks (Medical Center
ast, Birmingham, Ala); Dr Bleakley Chandler and Paula Easler
University Hospital, Augusta, Ga); Dr Eric Dippel and Penny
toakes (Genesis Medical Center, Davenport, Iowa); Dr Clay W
611.e1 The Journal of Thoracic and Cardiovascular Surgery ● Jurnett and Sandy Bernhardt (Olathe Medical Center, Olathe,
an); Dr A. David Slater and Elizabeth Cooke (Jewish Hospital,
ouisville, Ky); Dr James C. Todd III and Janine Uhrin (Peninsula
egional Medical Center, Salisbury, Md); Dr Norbert Baumgart-
er and Kathleen Mostek (Covenant Medical Center, Saginaw,
ich); Dr John Fetter and Liz Zappitello (Saint Mary’s Medical
enter, Duluth, Minn); Dr Timothy Kroshus and Julia Price (Ab-
ott Northwestern Hospital, Minneapolis, Minn); Dr Nicholas
ouchoukos and Nancy Nickerson (Missouri Baptist Medical
enter, St Louis, Miss); Dr Joseph Graham and Rita Stiles (St-
ohn’s Regional Medical Center, Joplin, Miss); Dr David Duncan
nd Sherry Duncan (Forsyth Medical Center, Winston–Salem,
C); Dr John Alexander and Ann Skye (Duke University Medical
enter, Durham, NC); Dr Paul H. Werner and Cheryl Zywicki
Saint Lukes Medical Center, Milwaukee, Wis); Dr Mohammed
uader and Jacque Taylor (University Nebraska Medical Center,
apillion, Neb); Dr Roberto Novoa and Patricia Boyd (Aultman
ospital, Canton, Ohio); Dr Benjamin Sun and Ana Moore (Ohio
tate University Medical Center, Columbus, Ohio); Dr Anoar
acharias and Robert Habib (St-Vincent Mercy Medical Center
nd Saint Luke’s Hospital, Toledo, Ohio); Dr Sanjay Mehta and
aula Ulsh (Milton S. Hershey Medical Center, Hershey, Pa); Dr
aul Risher and Eileen Taff (Saint Luke’s Hospital, Bethlehem,
a); Dr Robert Hagberg and Jennine Zumbuhl (Sentara Norfolk
eneral Hospital, Norfolk, Va); Dr Frederick Armenti and Sandy
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